Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings, Inc. develops therapies for central nervous system, inflammatory and cardiometabolic diseases as a late-stage biopharmaceutical company. News about RVPH centers on brilaroxazine (RP5063), a clinical-stage program for schizophrenia and other neuropsychiatric indications, as well as RP1208, with both drug candidates described as new chemical entities discovered in-house.
Recurring updates include clinical and regulatory communications, intellectual-property strategy, peer-reviewed data publications, corporate presentations, annual and interim financial results, and equity or warrant financings used to support research and development and working capital.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced positive results from its Phase 2 clinical trial for RP5063 (brilaroxazine) aimed at treating Acute Schizophrenia in 234 patients. The trial successfully met its primary endpoint by demonstrating a significant reduction in the Positive and Negative Syndrome Scale (PANSS) total score by 20 points compared to placebo. Importantly, the drug showed improved safety with no metabolic or endocrine side effects. Reviva is optimistic about obtaining a 'Superior Safety' label claim from the FDA pending results from a pivotal Phase 3 study.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has successfully closed its merger with Tenzing Acquisition Corp, marking its public listing. The company reported a 2020 net loss of $3.8 million, compared to $847,000 the previous year. Reviva plans to initiate a pivotal Phase 3 trial for its lead asset, brilaroxazine, targeting schizophrenia. The trial is expected to start in mid-2021, contingent on achieving fundraising goals. As of December 31, 2020, Reviva had $8.8 million in cash, allowing it to cover operating expenses through 2021.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced its participation in the Maxim Group Inaugural Emerging Growth Virtual Conference scheduled for March 17-19, 2021. The company will feature a pre-recorded presentation and engage in a live fireside chat on March 17 from 4:30 – 5:00 pm ET. Webcasts will be accessible via the conference portal and Reviva's investor website. Reviva focuses on developing therapies for unmet medical needs in CNS, cardiovascular, and metabolic diseases, with pipeline candidates RP5063 and RP1208.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced its participation at the H.C. Wainwright Global Life Sciences Conference, held virtually on March 9-10, 2021. Attendees can access a pre-recorded presentation on-demand starting March 9 at 7 a.m. ET. Reviva focuses on developing therapies for the central nervous system, cardiovascular, metabolic, and inflammatory diseases, with its lead candidate, RP5063 (brilaroxazine), targeting schizophrenia and other mental health disorders. The company is committed to addressing unmet medical needs amidst industry challenges.
Reviva Pharmaceuticals Holdings, Inc. has successfully completed its merger with Tenzing Acquisition Corp., transitioning to the ticker symbols RVPH for common stock and RVPHW for warrants effective December 15, 2020. This combination enables Reviva to access public markets and drive clinical development of its lead drug, Brilaroxazine (RP5063), which is positioned to address unmet needs in CNS and respiratory diseases. The partnership aims to enhance shareholder value and expedite treatment advancements, particularly for schizophrenia and pulmonary hypertension.